Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 18, 2000

View Archived Issues

Butyric acid compounds may offer antigen-specific immunotherapy

Aradigm completes phase II trial with AERx delivery of dornase alfa for CF patients

Glucophage XR: once-daily type 2 diabetes drug approved by FDA

Merger of Corixa and Coulter to create comprehensive immunotherapy company

Preliminary human safety and PK/PD findings reported for Z-13752A

Potent Na+/H+ exchange inhibitor TY-12533 displays excellent cardioprotective profile in vivo

Novartis and Bristol-Myers Squibb enter alliance for IBS and autoimmune therapy

Newest TZD approved in Europe for type 2 diabetes

Development of vaccine for genital warts discontinued

Roche creates Basilea Pharmaceutica

Inflammatory disease collaboration announced by Serono and British Biotech

Dimethaid Research seeks approval for topical osteoarthritis treatment in Canada

Second IND filed in Canada for Theratechnologies' GH-releasing analogue

Esperion acquires biotechnology company; LUV program proceeds ahead of schedule

Priority review status issued for Xyrem

NIH supports HIV research at Progenics with funding

Molecumetics and Athersys to codevelop small-molecule drugs

Bimoclomol derivative with improved pharmacological profile identified at Biorex

Peptide derivatives from Aventis modulate basement membrane synthesis

U.K. researchers patent glycopeptides that enhance T-cell proliferation

Nortran's new ion channel blockers useful as antiarrhythmics

New agents for herpesvirus infections described by Bayer

GnRH antagonists as a focus of research at Merck

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 15, 2026.
SERPINB1 as potential biomarker for spinocerebellar ataxia type 2
BioWorld Science
Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
JPM 2026: Year kicks off with biopharma Q4 revenue and guidance
BioWorld
It was a battle of the companies with drugs for transthyretin-mediated amyloidosis on the first day of the J.P. Morgan 2026 Healthcare Conference with Alnylam...